Adult Vaccines Market

Adult Vaccines Market Forecast and Outlook By Fact.MR

• In 2025, the adult vaccines market was valued at USD 29.0 billion.
• Based on Fact.MR analysis, demand for adult vaccines is estimated to grow to USD 31.0 billion in 2026 and USD 59.8 billion by 2036 with CAGR of 6.8% during the forecast period.

Summary of Adult Vaccines Market

• Demand Drivers
  • Aging populations are increasing demand for influenza and pneumococcal vaccines. Preventive healthcare utilization supports market expansion.
  • Pharmacy vaccination services are improving adult vaccine accessibility. Expanded administration points support immunization uptake.
  • Public health agencies are strengthening adult vaccination recommendations. Immunization coverage targets support vaccine demand.
• Key Segments Analyzed
  • By Vaccine Type: Influenza accounts for 35.0% share in 2026 due to annual immunization requirements.
  • By Technology Platform: Recombinant/Subunit contributes 30.0% share in 2026 supported by broad commercial adoption.
  • By Immunization Type: Routine vaccination captures 60.0% share due to established healthcare schedules.
  • By Distribution Channel: Hospital Pharmacies register 45.0% share in 2026 supported by vaccine administration infrastructure.
  • By End User: Adults Aged 50 Years and Above account for 50.0% share due to higher disease susceptibility.
  • By Geography: China is projected to record 8.4% CAGR through 2036 supported by adult vaccination expansion.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, “Growth opportunities are concentrated in aging population vaccination and pharmacy-administered immunization services. Organizations that strengthen adult vaccine access are likely to improve market positioning.”
• Strategic Implications
  • Vaccine manufacturers should strengthen adult immunization awareness programs. Better awareness improves vaccination coverage.
  • Healthcare providers should expand pharmacy-based vaccination services. Convenient access improves immunization rates.
  • Manufacturers should invest in combination vaccine development. Product differentiation supports commercial growth.

The market is projected to generate approximately USD 28.8 billion in additional revenue between 2026 and 2036. Expansion is supported by rising adult immunization coverage and broader use of preventive healthcare services. Demand benefits from aging populations and stronger vaccination recommendations. Budget pressure within public health systems moderates value expansion.

China is expected to record 8.4% CAGR supported by expansion of adult immunization programs. India is projected to grow at 8.1% CAGR due to rising private vaccination spending. Brazil is forecast to expand at 7.3% CAGR supported by broader vaccine access through healthcare clinics. The United States is estimated to witness 6.2% CAGR due to strong pharmacy vaccination networks. Germany is likely to register 5.8% CAGR supported by reimbursement coverage. Japan is projected to advance at 5.5% CAGR due to increasing elderly vaccination uptake.

Segmental Analysis

Adult Vaccines Market Analysis by Vaccine Type

Influenza is estimated to hold 35.0% share in 2026. Annual vaccination recommendations support recurring demand across adult populations. Public health agencies prioritize influenza prevention due to seasonal disease burden. Novavax announced a non-exclusive licensing agreement with Pfizer allowing Pfizer to use Novavax's Matrix-M adjuvant technology in vaccine development for up to two infectious disease areas. Novavax will receive a $30 million upfront payment, is eligible for up to $500 million in development and sales milestones, and may earn royalties on future product sales. [1]

• Seasonal Protection: Annual influenza outbreaks support recurring vaccination demand. Public health campaigns improve vaccine uptake.
• Employer Programs: Workplace vaccination initiatives support immunization among working adults. Occupational coverage contributes to demand.
• Elderly Coverage: Older adults receive priority vaccination recommendations. Age-related risk supports utilization.

Adult Vaccines Market Analysis by Technology Platform

Recombinant vaccines are estimated to account for 30.0% share. The platform supports strong safety profiles and broad use across adult vaccination programs. Commercial deployment across shingles and influenza vaccines strengthens demand concentration.

• Product Acceptance: Recombinant platforms support established physician confidence. Clinical utilization supports segment demand.
• Manufacturing Scale: Producers maintain large commercial manufacturing capacity. Supply availability supports adoption.
• Disease Coverage: Multiple adult vaccines utilize recombinant technology. Broad application supports revenue generation.

Adult Vaccines Market Analysis by Immunization Type

Routine immunization is estimated to capture 60.0% share in 2026. National vaccination schedules support recurring vaccine administration throughout adulthood. Preventive healthcare initiatives strengthen participation across healthcare systems. Pfizer’s RSV vaccine ABRYSVO was approved by the U.S. FDA for adults aged 18–59 years who are at increased risk of RSV disease, expanding protection beyond older adults and pregnant populations. The approval is based on Phase 3 MONeT trial data and significantly expands the adult RSV vaccine market by including younger high-risk adults with chronic conditions such as diabetes, COPD, and heart disease. [2]

• Schedule Compliance: Healthcare providers promote routine adult immunization. Clinical recommendations support coverage.
• Public Programs: Government-backed vaccination initiatives support utilization. Preventive healthcare policies encourage participation.
• Booster Demand: Adult booster schedules require periodic vaccination. Recurring administration supports market value.

Adult Vaccines Market Analysis by Distribution Channel

Hospital pharmacies are estimated to hold 45.0% share in 2026. Hospital-based vaccination remains a primary administration pathway across adult healthcare systems. Clinical supervision supports utilization for high-risk populations. Sanofi announced completion of its acquisition of Dynavax Technologies, adding HEPLISAV-B, a licensed adult hepatitis B vaccine, to its commercial vaccine portfolio and strengthening its focus on adult immunization growth. [3]

• Clinical Access: Hospitals provide vaccination during routine healthcare visits. Established infrastructure supports demand.
• High-Risk Coverage: Immunocompromised adults frequently receive vaccines through hospitals. Specialist care supports utilization.
• Vaccine Storage: Hospital facilities maintain cold-chain capability. Storage reliability supports distribution concentration.

Adult Vaccines Market Analysis by End User

Adults aged 50 years and above are estimated to register 50.0% share. Higher susceptibility to infectious diseases supports vaccination rates across this population. Recommendations for influenza and shingles vaccines strengthen utilization. Moderna received U.S. FDA approval for its RSV vaccine mRESVIA for adults aged 18–59 years at increased risk of RSV disease, expanding its use beyond the previously approved 60+ population. The expanded indication is supported by Phase 3 trial data showing strong immune responses and safety in younger high-risk adults. [4]

• Disease Risk: Aging populations face greater infection risk. Preventive vaccination supports healthcare outcomes.
• Physician Recommendations: Healthcare providers actively recommend vaccination. Clinical guidance supports demand.
• Preventive Healthcare: Older adults participate more frequently in vaccination programs. Healthcare engagement supports utilization.

Drivers, Restraints, and Opportunities

Adult vaccine demand is shifting from seasonal vaccination toward lifetime immunization strategies. Early market development focused on influenza prevention. Current demand increasingly reflects broader protection against respiratory infections and age-related disease risks. During 2025, several national immunization agencies expanded adult vaccine recommendations for aging populations.

Healthcare spending patterns are influencing vaccine adoption across developed and emerging markets. Adult immunization remains underpenetrated compared with pediatric vaccination. Public awareness campaigns and pharmacy vaccination services are improving coverage rates. Cost constraints within public healthcare systems limit faster expansion. The U.S. FDA approved an expanded indication for AREXVY, allowing use in adults aged 50–59 years who are at increased risk of RSV disease. This made AREXVY the first RSV vaccine approved for this younger at-risk adult population. [5]

• Aging Population: Population aging increases exposure to respiratory and infectious diseases. Vaccination programs are expanding coverage among older adults.
• Pharmacy Vaccination: Retail pharmacy immunization services improve accessibility. Expanded administration networks support vaccination uptake.
• Policy Support: Adult vaccination recommendations from public health agencies strengthen immunization adoption. National programs support long-term demand.

Regional Analysis

The adult vaccines market is assessed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study evaluates adult immunization coverage, healthcare spending, vaccination policy, pharmacy administration networks, and preventive healthcare adoption across major countries.

Opportunity Analysis of Adult Vaccines Market in China

China is projected to expand at 8.4% CAGR through 2036 as adult immunization receives stronger policy attention and healthcare investment. Demand is concentrated in influenza vaccination and pneumococcal protection among aging populations. Private vaccination clinics benefit from rising preventive healthcare spending. Imported vaccine brands maintain strong acceptance across urban healthcare centers.

• Adults increasingly purchase preventive vaccines through private vaccination clinics.
• Influenza and pneumococcal vaccines attract strong interest among older populations.
• Vaccine suppliers focus on expanded clinic access and broader adult immunization coverage.

Sales Analysis of Adult Vaccines Market in India

India is expected to record 8.1% CAGR through 2036 supported by rising private healthcare spending and growing awareness of adult immunization. Corporate vaccination programs are expanding across large employers. Private hospitals play an important role in vaccine administration. Urban healthcare networks are promoting preventive vaccination among middle-income populations.

• Corporate vaccination initiatives support demand across working adults.
• Private hospitals strengthen access to influenza and pneumococcal vaccines.
• Manufacturers focus on awareness campaigns and physician engagement programs.

Demand Assessment of Adult Vaccines Market in Japan

Japan is expected expand at 5.5% CAGR through 2036 as demographic aging increases focus on preventive healthcare. Municipal vaccination support programs encourage participation among older adults. Pneumococcal vaccination remains an important public health priority. Demand reflects greater attention toward healthy aging and disease prevention.

• Elderly populations account for a substantial share of vaccine demand.
• Municipal healthcare programs support preventive vaccination uptake.
• Manufacturers focus on vaccines associated with healthy aging initiatives.

Demand Outlook for Adult Vaccines Market in Brazil

Brazil is forecast to advance at 7.3% CAGR through 2036 as public immunization campaigns strengthen adult vaccine participation. Influenza vaccination remains a major component of adult preventive healthcare. Private healthcare providers are expanding access to shingles and pneumococcal vaccines. Demand reflects rising healthcare engagement among aging populations.

• Adults participate in seasonal vaccination programs through public healthcare networks.
• Private clinics are expanding availability of adult preventive vaccines.
• Vaccine suppliers strengthen distribution through regional healthcare partnerships.

In-depth Analysis of Adult Vaccines Market in United States

The United States is projected to grow at 6.2% CAGR through 2036 supported by strong pharmacy vaccination infrastructure and established adult immunization guidelines. Pharmacy chains administer a substantial share of seasonal vaccines. Shingles vaccination demand remains strong among adults aged above 50 years. Medicare coverage supports access to recommended vaccines.

• Pharmacy-administered vaccination contributes substantially to adult immunization volumes.
• Shingles and influenza vaccines maintain strong demand among older adults.
• Vaccine manufacturers focus on coverage expansion and booster compliance initiatives.

Opportunity Analysis of Adult Vaccines Market in Germany

Germany is anticipated to register 5.8% CAGR through 2036 supported by reimbursement coverage and established vaccination recommendations. Adult immunization demand is concentrated in influenza and pneumococcal vaccination. Physicians play an important role in vaccine uptake across older populations. Public healthcare coverage supports access to preventive services.

• Reimbursed vaccination programs improve adult vaccine accessibility.
• Influenza vaccination remains a routine preventive healthcare measure.
• Healthcare providers promote higher participation among elderly populations.

Competitive Aligners for Market Players

The competitive structure reflects the presence of multinational vaccine manufacturers with established commercial portfolios. Product breadth and regulatory approvals influence competitive positioning. Organizations with diversified vaccine offerings maintain stronger healthcare system engagement.

Companies with global manufacturing networks benefit from supply reliability and broad distribution access. Long-term relationships with healthcare authorities strengthen commercial visibility. Vaccine development capabilities support portfolio expansion across adult immunization applications.

Healthcare providers evaluate vaccines based on efficacy and availability. Public immunization programs influence purchasing volumes across major markets. Established manufacturers benefit from strong physician confidence and extensive clinical evidence. Commercial positioning is increasingly linked to adult vaccination awareness and healthcare accessibility. Companies that strengthen pharmacy distribution and healthcare provider engagement improve market reach. Growth opportunities are concentrated in aging population vaccination and preventive healthcare services.

Key Players

• Pfizer Inc.
• Moderna, Inc.
• GlaxoSmithKline plc (GSK)
• Sanofi
• Merck & Co., Inc.

Bibliography

• [1] Novavax, Inc. (2026, January 20). Novavax announces entering into a license agreement with Pfizer.
• [2] Pfizer Inc. (2024, October 22). U.S. FDA approves Pfizer’s RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease.
• [3] Sanofi. (2026, February 10). Sanofi completes the acquisition of Dynavax.
• [4] Moderna, Inc. (2025, June 12). Moderna receives U.S. FDA approval for RSV vaccine, mRESVIA, in adults aged 18–59 at increased risk for RSV disease.
• [5] GSK plc. (2024, June 7). U.S. FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50–59 at increased risk.

This Report Addresses

• Analysis of adult vaccine demand across preventive healthcare and immunization programs.
• Market forecast from USD 31.0 billion in 2026 to USD 59.8 billion by 2036 at 6.8% CAGR.
• Opportunity assessment across influenza, pneumococcal, shingles, and booster vaccination applications.
• Segment forecasts covering vaccine type, technology platform, immunization type, distribution channel, and end user demand.
• Competitive assessment of multinational vaccine manufacturers and commercial positioning.
• Evaluation of adult immunization coverage trends and healthcare policy developments.
• Country-level analysis across China, India, Brazil, the United States, Germany, and Japan.
• Report delivery through PDF and Excel formats supported by primary interviews and industry analysis.

Adult Vaccines Market Definition

Adult vaccines are biological products administered to individuals aged 18 years and above for protection against infectious diseases. These vaccines reduce disease burden and support preventive healthcare strategies. Products include seasonal vaccines and long-term protection vaccines. Demand is concentrated in influenza prevention, pneumococcal disease prevention, shingles prevention, and adult booster immunization programs. Market activity reflects healthcare policy, immunization recommendations, reimbursement coverage, and vaccine accessibility.

Adult Vaccines Market Inclusions

The study covers global and regional forecasts from 2026 to 2036 by vaccine type, technology platform, immunization type, distribution channel, and end user. It includes adult preventive vaccines, routine vaccination programs, travel vaccines, occupational vaccines, and pandemic immunization programs across major healthcare markets.

Adult Vaccines Market Exclusions

The study excludes pediatric vaccines and veterinary vaccines. It omits childhood immunization programs and experimental vaccine candidates without commercial deployment. Therapeutic vaccines are excluded unless directly linked to adult preventive immunization use.

Adult Vaccines Market Research Methodology

• Primary Research
  • Interviews were conducted with vaccine manufacturers, hospital pharmacists, immunization specialists, infectious disease physicians, and healthcare administrators across major regions.
• Desk Research
  • Analysis included company disclosures, WHO publications, CDC recommendations, immunization program updates, and vaccine industry developments published during 2024, 2025, and January 2026.
• Market-Sizing and Forecasting
  • Hybrid top-down and bottom-up model using vaccine utilization data, immunization coverage trends, public healthcare spending, and manufacturer revenue estimates.
• Data Validation and Update Cycle
  • Forecast was validated through distributor interviews, company disclosures, vaccination program data, and healthcare provider feedback.